What's Going On With Tonix Pharmaceuticals Stock Friday?
Portfolio Pulse from Dylan Berman
Tonix Pharmaceuticals (NASDAQ:TNXP) shares rose 17.2% after the company received a patent for subcutaneous delivery of Zembrace Symtouch for migraines, valid until 2036. This follows a campaign promoting non-oral migraine treatments.
September 27, 2024 | 4:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals' stock surged 17.2% following the grant of a new patent for subcutaneous delivery of Zembrace Symtouch for migraines, providing protection until 2036. This development is part of a broader campaign to promote non-oral migraine treatments.
The issuance of a new patent for a migraine treatment method is a significant development for Tonix Pharmaceuticals, likely boosting investor confidence and driving the stock price up. The patent provides long-term protection, enhancing the company's competitive position in the migraine treatment market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100